Bayer Execs Silent On Plans To Divest Material Sciences
This article was originally published in The Pink Sheet Daily
Executive Summary
The diversified German big pharma highlighted the sales growth of its five recently launched drugs in the first quarter, but declined to fuel M&A speculation surrounding its non-life sciences division.